

VANCOMYCIN INDUCED RASHES -A CASE SERIES REPORT

V.SANKAR¹, S.M.VITHUNES*

¹Department of Pharmaceutics, PSG College of Pharmacy, Coimbatore, Tamilnadu-641004, India

* Department of Pharmacy Practice, PSG College of Pharmacy, Coimbatore,
Tamilnadu-641004, India

ABSTRACT:

Vancomycin is a bacterial antibiotic used against resistant strains of streptococcus and staphylococcus, and one of the higher antibiotics to be used in treatment for the infections occurred in heart valve disease and in severe sepsis patients above 60 years. The main of the study is to determine the major clinical side effects of the vancomycin. It was a open label prospective and retrospective study. Among the 170 vancomycin injection received patients in the hospital with same brand, dose and frequency (1gm IV slow infusion) seventeen patients was observed with rashes over the neck and upper lymph. It is known as Red Man Syndrome or Dress Syndrome. In this study one patient associated with anaemia the dosing interval changed to prevent severe anaemia and another patient the drug was stopped because of severe reaction. The test dosing (10 microgram/ml) concept can be introduced before the administration of routine dose to minimize the clinical side effects. The treatment with antibiotic (linezolid or tigecycline) can be used as alternative.

Key words: Vancomycin, Central vein, Red man syndrome, Rashes, Dose adjustment.

1. INTRODUCTION

Vancomycin is a antibiotic against resistant strains of streptococcus and staphylococcus. It is used to treat infection of intestines caused by clostridium difficile, which can cause watery or bloody diarrhoea [1]. Additionally it is used in treatment of staph infections that causes inflammation of the colon and small intestines. Oral vancomycin works only in intestines and not as effective in other infections [2]. An injection form is used to treat serious infections in other parts of the body. Some of the major side effects include rashes in the site of administration and upper lymph

near neck more over long time side effect of this vancomycin include hearing loss [3]. In pregnancy category it is not known if vancomycin harms the baby or not and the study is still in process to prove its safety [4]. It also passes into the breast milk and may harm a nursing baby [5]. In kidney failure patients it should be used with caution as it may worsen the condition of renal failure [6]. The main objective of the study is to know more about the major clinical side effects of vancomycin induced rashes [7].

2. MATERIALS AND METHODS:

2.1 STUDY SITE & STUDY POPULATION:

The study was conducted in a 900 bedded multispeciality hospital. The study population included the adult patients who were using vancomycin in their treatment. Study population also includes only the patients taking injection form of the drug vancomycin in their treatment. Pregnancy women, paediatric patients were in exclusion criteria [8].

2.2 STUDY DESIGN:-

This study is designed under both retrospective & prospective study. The patients using vancomycin injection in the year of 2015 were included in the study. A data collection form was designed with the Inclusion of complete blood count, Renal Parameters & Physical Observation of Erythema. [9]

We have screened the patients using vancomycin for the clinical side effects. Study protocol was prepared and submitted to the IHEC. After ethical approval, patients using vancomycin was screened for clinical side effects and data was recorded.

3. RESULTS:


3.1 TOTAL NUMBER OF PRESCRIPTION SCREENED:

During the study period 170 patients was treated with vancomycin. Out of that 17 patients had rashes around their neck and upper lymph.

Table 1: Details of Patients in the study

SL.NO	CATEGORY	No Of Patient
1	Total No of patients screened	170
2	Patients observed with ADR	17

FIGURE-1 Percentage Presence and Absence of ADR



4. DISCUSSION:

The Red Man Syndrome effect due to vancomycin was observed in 10% of the patients (Fig 2) taking 1gm IV slow infusion but literature reports state 47.9 % [10] .The infusion in central vein is the major reason for the red man syndrome. The drug usage and its time interval was altered on the basis of the severity monitoring of the patient and the biological half life of vancomycin[11]. The patients who are sensitive to drug by nature and genetically will show the side effects of red man syndrome.

FIGURE 2:- Patient With Red Man Syndrome



Steroids can be used for the management of red man syndrome. Parenteral vancomycin can be changed to oral route of administration[12]. Niranjo ADR assessment scale confirms the ADR was found to be a definite ADR and the

score was found to be 9. Vancomycin showed the adverse reaction and once the drug was withdrawn it was stopped and when the drug was exposed again it reappeared

5. CONCLUSION:

The test dosing (10 microgram/ml) concept can be introduced before the administration of routine dose to minimize the clinical side effects of vancomycin[13]. The treatment with antibiotic (linezolid or tigecycline) can be used as alternative [14]. We can minimise this ADR by giving the next dose of vancomycin after its half life period[15].

6. ACKNOWLEDGEMENT:

We would like to thank PSG College of Pharmacy, PSG hospitals, clinical sites, and the patients for their support and cooperation. We also thank Miss Deepthi Wilson for her extensive English proof reading and editing services.

7. AUTHORS CONTRIBUTION:

Work plan: Veintramuthu Sankar; Data collection, Analysis and interpretation, Writing the article Statistical analysis- S.M.Vithunes, Final approval of the article, Overall responsibility: Veintramuthu Sankar.

8. CONFLICTS OF INTEREST:

The authors declare no conflict of interest.

REFERENCES:

1. Eggimann P, Pittet D. Infection control in the ICU. *Chest*. 2001;120:2059–2093.
2. Lori WaznyD, Behnam D. Desensitization protocols for vancomycin hypersensitivity. *Ann Pharmacother*. 2001;35:1458–1464
3. .Davis RL, Smith AL, Koup JR. The 'red man's syndrome' and slow infusion of vancomycin [letter]. *Ann Intern Med*. 1986;104:285–286.
4. Korman T, Turnidge J, Grayson M. Risk factors for cutaneous reactions associated with intravenous vancomycin. *J Antimicrob Chemother*. 1997;39:371–381.
5. Williams PD, Laska DA, Shetler TJ, McGrath JP, White SL, Hoover DM. Vancomycin-induced release of histamine from rat peritoneal mast cells and a rat basophil cell line (RBL-1). *Agents Actions*. 1991;32:217–223.

6. Supramanian sivagnanam, Ross M. Red-man syndrome: a preventable adverse drug reaction in critical care. *J Infect Dis.* 2003;191(2):published online 2002 dec 23.
7. Wallace M, Mascola J, Oldfield E, III. Red-man syndrome: Incidence, etiology, and prophylaxis. *J Infect Dis.* 1991;164:1180–1185.
8. Polk RE, Healy DP, Schwartz LB, Rock DT, Garson ML, Roller K. Vancomycin and the red-man syndrome: pharmacodynamics of histamine release. *J Infect Dis.* 1988;157:502–507.
9. Healy DP, Sahai JV, Fuller SH, Polk RE. Vancomycin-induced histamine release and red man syndrome: comparison of 1- and 2-hour infusions. *Antimicrob Agents Chemother.* 1990;34:550–554.
10. Sahai J, Healy DP, Garris R, Berry A, Polk RE. Influence of antihistamine pre-treatment on vancomycin induced red-man syndrome. *J Infect Dis.* 1989;160:876–881.
11. Wallace MR, Mascola JR, Oldfield EC. Red man syndrome: incidence, aetiology and prophylaxis. *J Infect Dis.* 1991;164:1180–1185.
12. Miller R, Tausk HC. Anaphylactoid reaction to vancomycin during anaesthesia: a case report. *Anest Analg.* 1977;56:870–872.
13. Southorn PA, Plevak DJ, Wright AJ, Wilson WR. Adverse effects of vancomycin administered in the perioperative period. *Mayo Clin Proc.* 1986;61:721–724.
14. Polk RE, Israel D, Wang J, Venitz J, Miller J, Stotka J. Vancomycin skin tests and prediction of red man syndrome in healthy volunteers. *Antimicrob Agents Chemother.* 1993 Oct; 37(10): 2139–2143.
15. Yeon An So, Kyung Hwang Eui-, Hee Kim Joo, Eun Kim Jeong, Jung JinHyun, Min Jin Sun, Kyun Jin Ok, Hee Lee Young, Sim Park Hae, Young Wha Choi, Kwan Lim Seung, Min Ye Young. Vancomycin-Associated Spontaneous Cutaneous Adverse Drug Reactions. *Allergy asthma immunol res v.3(3);2011 jul.*